| Patents for A61K 45 - Medicinal preparations containing active ingredients not provided for in groups (115,020) |
|---|
| 06/22/2011 | EP1773395B1 A method for managing cholesterol with a serum-free and mitogen free cytokine mixture |
| 06/22/2011 | EP1718155B1 Methods of use of probiotic bifidobacteria for companion animals |
| 06/22/2011 | EP1596872B1 Compositions and methods for restoring bacterial flora |
| 06/22/2011 | EP1328545B1 Human gene critical to fertility |
| 06/22/2011 | EP1207876B1 Use of a modulator which acts on a growth factor precursor in order to inhibit growth factor precursor processing |
| 06/22/2011 | EP1204683B1 Ovarian cancer cell and myeloma cell surface glycoproteins, antibodies thereto, and uses thereof |
| 06/22/2011 | CN1964723B Use of fine grain of macromolecule in preparing transparent tissue visualizing agent |
| 06/22/2011 | CN1903364B Medicine composition containing inhibitor of angiotonase and phenoxy acid compounds |
| 06/22/2011 | CN1447819B Human CYR 61 |
| 06/22/2011 | CN102105789A Brown adipocyte progenitors in human skeletal muscle |
| 06/22/2011 | CN102105170A Antifungal combination therapy |
| 06/22/2011 | CN102105169A Pharmaceutical compositions for treatment of parkinson's disease |
| 06/22/2011 | CN102105168A Therapeutic agent for migraine |
| 06/22/2011 | CN102105167A Prophylactic or therapeutic agent for axial myopia |
| 06/22/2011 | CN102105152A Therapeutic combination comprising a cdks inhibitor and an antineoplastic agent |
| 06/22/2011 | CN102105151A Use of a CDK inhibitor for the treatment of glioma |
| 06/22/2011 | CN102105148A Therapeutic combination comprising an AURORA kinase inhibitor and antiproliferative agents |
| 06/22/2011 | CN102105147A Therapeutic combination comprising an AURORA kinase inhibitor and an antineoplastic agent |
| 06/22/2011 | CN102105142A Compositions for treating rosacea comprising chitosan and a dicarboxylic acid |
| 06/22/2011 | CN102105135A Modified drugs for use in liposomal nanoparticles |
| 06/22/2011 | CN102100913A Target spot and medicine for treating cerebral injury |
| 06/22/2011 | CN102100912A Administration composition and preparation method and using method thereof |
| 06/22/2011 | CN102100665A Eye drops containing vitamin E derivatives and preparation method thereof |
| 06/22/2011 | CN101773483B Preparation method of water-insoluble drug microcapsule |
| 06/22/2011 | CN101044247B Compositions, kits, and methods for identification, assessment, prevention, and therapy of cervical cancer |
| 06/21/2011 | US7964713 Nucleotide sequences which code polypeptide for use in human therapeutics ad diagnostics |
| 06/21/2011 | US7964703 DNAX Cytokine Receptor Subunits (DCRS) 5 cytokine receptors modulators; multiple sclerosis, rheumatoid arthritis, osteoarthritis, inflammatory bowel disease, diabetes, psoriasis, sepsis or in allogeneic transplant; chronic Th1 mediated disease |
| 06/21/2011 | US7964644 Use of neurotoxic substances for the production of a means for the treatment of joint paint and method for application of said means |
| 06/21/2011 | US7964609 Use of mGluR5 antagonists for the treatment of gerd |
| 06/21/2011 | US7964587 Tocopherol and tocotrienol aerosols |
| 06/21/2011 | US7964568 Synthesis of high molecular weight iron-saccharidic complexes |
| 06/21/2011 | US7964400 Immune potentiating compositions of cancer cells |
| 06/21/2011 | US7964398 Modified vaccinia ankara virus variant and cultivation method |
| 06/21/2011 | US7964397 Method for the cultivation of primary cells and for the amplification of viruses under serum free conditions |
| 06/21/2011 | US7964395 Modified vaccinia ankara virus variant and cultivation method |
| 06/21/2011 | US7964220 Method for treating a mammal by administration of a compound having the ability to release CO |
| 06/21/2011 | US7964216 Orally administering to a patient a spaced drug delivery system, wherein first therapeutically active agent is released immediately and second therapeutically active agent is released as a pulse at predetermined time after administration |
| 06/21/2011 | US7964212 Effervescent compositions comprising phosphonates and methods related thereto |
| 06/21/2011 | US7964207 Reacting a naturally occurring polyol and a biocompatible, synthetic polyol and isocyanate which react to form a polyesterurethane; composition promotes bone growth when positioned in the vicinity of a bone of a mammal; use of multicompartment sealed container |
| 06/21/2011 | US7964190 Administering mixtures of antibodies and tumor necrosis factors, immunosuppressants, antibiotics, antiinflammatory agents, cytokines, angiogenesis inhibitors or fibroblast growth factors; prophylaxis of graft versus host disease |
| 06/21/2011 | US7964187 Sensitization of chemotherapeutic agent resistant neoplastic cells with a virus |
| 06/21/2011 | US7964186 modified adenovirus containing mutation in or lacks the virus associated RNA gene, modified HSV, vaccinia virus and parapoxvirus; Ras-activated pathway; neoplasm; immunosuppressant |
| 06/21/2011 | US7964183 Composition and dosage form comprising a particle formulation and suspending vehicle |
| 06/21/2011 | CA2635412C Agent for prophylaxis and treatment of asthenopia or pseudomyopia |
| 06/21/2011 | CA2486336C Pentafluorosulfanylbenzoylguanidines, process for their preparation, their use as medicament or diagnostic aid, and medicament comprising them |
| 06/21/2011 | CA2481602C Pharmaceutical composition comprising arsenite for the treatment of malignancy |
| 06/21/2011 | CA2472341C Phosphorus-containing compounds & uses thereof |
| 06/21/2011 | CA2472188C Polymeric gel system for the controlled delivery of codrugs |
| 06/21/2011 | CA2430934C A method of producing sustained-release preparations of a bioactive substance using high-pressure gas |
| 06/21/2011 | CA2407556C Gene detection assay for improving the likelihood of an effective response to an erbb antagonist cancer therapy |
| 06/21/2011 | CA2396785C A medicinal aerosol formulation |
| 06/21/2011 | CA2396648C A medicinal aerosol formulation |
| 06/21/2011 | CA2370775C Use of a serenoa repens extract for the production of a medicament to treat prostate cancer |
| 06/21/2011 | CA2370143C Esters of l-carnitine or alkanoyl l-carnitines useful as cationic lipids for the intracellular delivery of pharmacologically active compounds |
| 06/21/2011 | CA2323071C Molecules that home to various selected organs or tissues |
| 06/21/2011 | CA2320406C Methods of screening agents for activity using teleosts |
| 06/21/2011 | CA2172392C Methods of inhibiting phagocytosis |
| 06/16/2011 | WO2011071684A1 Oral rehydration solutions comprising dextrose |
| 06/16/2011 | WO2011071137A1 Therapeutic system for onychomycosis |
| 06/16/2011 | WO2011071136A1 Therapeutic agent for fibromyalgia |
| 06/16/2011 | WO2011071059A1 T cell activation inhibitor, pharmaceutical composition containing same, and screening method for t cell activation inhibiting substance |
| 06/16/2011 | WO2011070369A1 Inhibitors of hemopoietic cell kinase (p59-hck) and their use in the treatment of influenza infection |
| 06/16/2011 | WO2011070358A2 Product and method |
| 06/16/2011 | WO2011069932A1 Novel therapeutic uses for an ornithine alpha-ketoglutarate complex |
| 06/16/2011 | WO2011069527A1 Treatment scheme for idd and other automimmune diseases |
| 06/16/2011 | WO2011049948A3 Neuroprotection and myelin repair using nestorone® |
| 06/16/2011 | WO2011045068A3 Pharmaceutical composition containing cannabinoid-receptor 2 antagonists |
| 06/16/2011 | US20110144127 Agents for treatment of glaucomatous retinopathy and optic neuropathy |
| 06/16/2011 | US20110144072 Antiglucocorticoid Therapy for the Prevention of Neurological Damage in Premature Infants |
| 06/16/2011 | US20110144035 Methods and Compositions for Treating Conditions of the Eye |
| 06/16/2011 | US20110144015 Methods for treating muscle diseases and disorders |
| 06/16/2011 | US20110143995 Novel anti-allergic agents |
| 06/16/2011 | US20110143991 Peptides for Activation and Inhibition of Delta-PKC |
| 06/16/2011 | US20110142956 Use of a pde 5 inhibitor for treating and preventing hypopigmentary disorders |
| 06/16/2011 | US20110142953 Combinations of immunosuppressive agents for the treatment or prevention of graft rejections |
| 06/16/2011 | US20110142794 Methods and Compositions to Determine the Chemosensitizing Dose of Suramin Used in Combination Therapy |
| 06/15/2011 | EP2333069A2 Therapeutic uses of IL-17 homologous polypeptides |
| 06/15/2011 | EP2333065A1 Novel MHC class II restricted T cell epitopes from the cancer antigen, NY ESO-1 |
| 06/15/2011 | EP2332973A2 Differential in tumour gene products and use of same |
| 06/15/2011 | EP2332953A1 Substituted amine derivative and medicinal composition comprising same as the active ingredient |
| 06/15/2011 | EP2332952A1 Modified 2' and 3'-nucleoside prodrugs for treating flaviridae infections |
| 06/15/2011 | EP2332938A1 Viral inhibitors |
| 06/15/2011 | EP2332580A1 A composition for the treatment of the central nervous system |
| 06/15/2011 | EP2332579A2 Antibodies that bind human interleukin-18 and methods of making and using |
| 06/15/2011 | EP2332578A1 Methods of treating central nervous system ischemic or hemorrhagic injury using anti alpha4 integrin antagonists |
| 06/15/2011 | EP2332568A1 Collagenase for opening obstructed biological conduits |
| 06/15/2011 | EP2332561A1 Blockade of T lymphocyte down-regulation associated with CTLA-4 signaling |
| 06/15/2011 | EP2332553A1 Methods and compositions to treat myocardial conditions |
| 06/15/2011 | EP2332542A2 Use of methylol-containing compounds for the manufacture of a medicament for the treatment of tumors |
| 06/15/2011 | EP2332540A1 Administration of ranolazine for the treatment of diabetes |
| 06/15/2011 | EP2332537A1 Combinations of nicotinic acetylcholine alpha 7 receptor agonists |
| 06/15/2011 | EP2332531A1 Apo2 ligand/TRAIL formulations |
| 06/15/2011 | EP2332526A2 Combination of a renin-inhibitor and an anti-dyslipidemic agent and/or an antiobesity agent |
| 06/15/2011 | EP2332523A1 Uniform films for rapid dissolve dosage form incorporating taste-masking compositions |
| 06/15/2011 | EP2331210A2 Pharmaceutical combination of 3-(3-dimethylamino-1-ethyl-2-methyl-propyl)-phenol and an antiepileptic |
| 06/15/2011 | EP2331137A1 New combination of active ingredients containing an alpha-1antagonist and a pde 4 inhibitor |
| 06/15/2011 | EP2331102A1 Pharmaceutical combination comprising 6-dimethylaminomethyl-1-(3-methoxy-phenyl)-cyclohexane-1,3-diol and an nsaid |
| 06/15/2011 | EP2330897A1 Ngal-binding siderophores and use thereof to treat iron deficiency and iron overload |
| 06/15/2011 | EP1622616B1 Inhibitors of akt activity |
| 06/15/2011 | EP1404710B1 Identification of ses-3 (spr-5) in c. elegans and the uses of the same |